Flagicure

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Flagicure

Quick Facts

Property Description
Active Ingredient Metronidazole (INN)
Form Tablet, Capsule, Suspension, Solution (IV)
Pharmacological Class Nitroimidazole Antimicrobial
General Use Treatment of specific bacterial and protozoal infections
Origin Synthetic

Flagicure is a synthetic, prescription-only antimicrobial drug defined by its core component, the active ingredient metronidazole (INN). It is classified within the nitroimidazole pharmacological class, a category noted for its unique effectiveness against a specific spectrum of pathogens. This single-ingredient product is fundamentally employed to address and resolve systemic infections caused by susceptible microorganisms.


What Type of Medicine is Flagicure? (Definition and Classification)

Flagicure is categorized simultaneously as a specialized antibiotic and a potent antiprotozoal agent due to metronidazole's unique chemical action. This dual function is characteristic of the nitroimidazole class, allowing it to exert broad antimicrobial activity against both obligate anaerobic bacteria and certain parasitic protozoa, distinguishing it from conventional, single-spectrum antimicrobials. Metronidazole provides dual action against anaerobic bacteria and parasitic infections, serving as a primary agent for these conditions. Its pharmacological properties support the microorganism elimination required in these challenging clinical scenarios.


Flagicure's Composition and Physical Forms (Composition and Presentation)

The composition of Flagicure is built around the synthetic compound metronidazole, or its derivatives, which is combined with solid excipients for oral forms or an aqueous solution for injection and infusion. The drug is manufactured in a variety of dosage form(s), including oral tablets, capsules, oral suspension (often preferred for pediatric or geriatric patients), and sterile preparations for intravenous solution. This versatility ensures the medication can be administered via multiple routes of administration, such as Oral, Intravenous, Rectal, and Topical, providing flexibility based on the clinical necessity and the specific site of the infection.


What is the General Therapeutic Purpose of Metronidazole? (High-Level Benefit)

The general therapeutic purpose of Flagicure is to provide decisive microorganism elimination to clear the underlying infectious cause. Metronidazole functions as a prodrug that becomes activated inside the targeted pathogens, achieving a bactericidal and amebicidal effect by disrupting their DNA and inhibiting nucleic acid synthesis. The medication is utilized for its reliable efficacy in treating these infections globally. This utility underscores the medicine's role in resolving pathological conditions initiated by these specific anaerobic invaders and parasites.

Regulatory References

  1. NIH review on Metronidazole action

What side effects are possible with Flagicure?

Possible Side Effects and Safety Information

Adverse Reaction Scope

The safety profile of Flagicure (metronidazole) is characterized by effects categorized by frequency and the body system involved. The most Common adverse reactions reported in regulatory sources primarily involve the Gastrointestinal Disorders (e.g., nausea, vomiting, diarrhea, abdominal cramping) and often include a sharp metallic taste and headache. Less common reactions have been noted for the Blood and Lymphatic System (mild leukopenia).

Serious Adverse Reactions

Official labels document rare but serious adverse reactions, primarily affecting the Nervous System (including encephalopathy, seizures, and peripheral neuropathy). Severe irreversible hepatotoxicity/acute liver failure is documented, particularly in patients with Cockayne Syndrome, where use is contraindicated due to the high risk of fatal outcomes. The FDA label includes a Black Box Warning regarding the potential for carcinogenicity observed in animal studies, necessitating that its use be restricted to approved indications.

Safety Restrictions and Special Populations

Patients must avoid consumption of alcohol or products containing propylene glycol during therapy and for at least three days afterward due to the risk of a severe disulfiram-like reaction. Safety monitoring is recommended for patients with severe hepatic impairment or End-Stage Renal Disease (ESRD) due to the potential for drug or metabolite accumulation. Peripheral neuropathy has been reported with prolonged administration of the medicine.

Overdose and Emergency Response

Overdose and when to seek help

Official regulatory documents define the manifestations and required emergency actions in the event of a Flagicure (Metronidazole) overdose. Overdose presentations documented following single oral doses up to 15 grams have included nausea, vomiting, and ataxia (loss of muscle coordination). More severe neurotoxic effects, such as seizures and peripheral neuropathy (e.g., numbness or tingling), have been reported in the context of high, extended-course dosing.


Required Emergency Actions

Individuals who suspect an overdose must seek immediate medical attention. Regulatory guidance mandates contacting a poison control center or the emergency room at once. Emergency services should be called immediately if the individual has collapsed, had a seizure, has trouble breathing, or cannot be awakened.


Overdose Management Profile

Feature Regulatory Statement
Antidote Availability No specific antidote is known or available for metronidazole overdose.
Management Approach Treatment should consist only of symptomatic and supportive therapy.
Specific Population Risk Patients with Cockayne syndrome face a distinct risk of severe irreversible hepatotoxicity or acute liver failure, even at recommended doses, necessitating immediate drug discontinuation if symptoms of liver injury occur.

In the absence of a specific antidote, regulatory bodies stress that medical care must focus on supporting vital functions and managing the clinical signs that present.

Therapeutic Uses of Flagicure

What Flagicure Treats: Main Uses and Benefits

Flagicure is commonly used in situations involving symptoms related to specific conditions caused by obligate anaerobic bacteria and certain parasitic protozoa. Its primary therapeutic application includes managing symptoms associated with severe deep-seated infections like septicemia and abscesses; protozoal diseases such as amebiasis and giardiasis; and gynecological conditions like trichomoniasis and bacterial vaginosis (BV).

Therapeutic Scope and Support

The overall therapeutic role of Flagicure provides support that helps ease the overall symptom burden. Flagicure is applied in addressing conditions presenting with systemic or localized discomfort, which supports the body in managing symptoms related to systemic imbalance, such as high fever and severe, localized pain. The therapy is relevant for managing symptoms that interfere with daily comfort, such as persistent, painful diarrhea and abnormal vaginal discharge. Furthermore, in specific clinical contexts, it is applied prophylactically (preventatively) to help manage the risk of postoperative infection. This broad scope supports patients during difficult episodes by easing distress and assists with maintaining functional stability when symptoms become more disruptive.

Quick Fact: Support for Acute Symptom Manifestations
Main Symptom Axis Symptoms related to systemic imbalance and irritative states
Common Scenario Managing acute episodes of severe GI or deep-seated infection
Key Benefit Contributes to easing the overall symptom load

Eligibility and Restrictions for Use

The eligibility for Flagicure (metronidazole) is strictly governed by regulatory classifications, defining who can and who must not use the medicine, based on official labeling.

Contraindicated Populations

Flagicure is contraindicated in patients with a history of hypersensitivity to metronidazole or any related nitroimidazole derivative. Use is also strictly prohibited for patients who have taken disulfiram within the preceding two weeks, due to the risk of severe reactions. A specific, explicit contraindication applies to patients with Cockayne syndrome, given the documented risk of severe, rapid-onset hepatotoxicity.

Conditional Use and Age Restrictions

Use in certain populations is restricted or conditional. For many indications, the safety and efficacy of Flagicure are not established in the general pediatric population. Use in the geriatric population requires caution due to an increased likelihood of age-related liver function changes.

Patients with severe hepatic impairment (Child-Pugh C) require an officially recommended 50% dosage reduction due to impaired drug clearance. Caution is also warranted for patients with a history of seizures or certain CNS diseases, and for those with blood dyscrasias. Furthermore, the medicine is generally contraindicated during the first trimester of pregnancy for treating trichomoniasis.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile for Flagicure (Metronidazole) is defined by pharmacokinetic changes and strict administration constraints documented in regulatory labeling. The highest level of restriction involves specific substances that are contraindicated due to the risk of severe reactions.

Contraindicated Combinations

Substance/Product Interaction Outcome Administration Rule
Disulfiram Risk of psychotic reactions Contraindicated within the last two weeks
Alcohol/Propylene Glycol Disulfiram-like reaction (e.g., flushing) Contraindicated during and for at least three days after therapy

Pharmacokinetic and Pharmacodynamic Interactions

Flagicure co-administration officially affects the systemic exposure of several drugs through metabolic interaction patterns. Phenytoin and Phenobarbital accelerate the metabolism of Flagicure, reducing its plasma concentrations. Conversely, co-administration with Cimetidine may reduce Flagicure's clearance, potentially leading to increased plasma concentrations.

Flagicure also reduces the clearance of co-administered agents, officially increasing the plasma levels and risk of toxicity for drugs such as Busulfan and 5-Fluorouracil. Furthermore, Flagicure is officially documented to potentiate the anticoagulant effect of Warfarin and related coumarin drugs, resulting in the prolongation of prothrombin time.

Population-Specific Restrictions

Systemic use of Flagicure is contraindicated in patients with Cockayne Syndrome due to reported risks of severe, irreversible hepatotoxicity. Patients with severe hepatic impairment may also experience delayed clearance and accumulation of Flagicure.

Mechanism of Action

Prodrug Activation and Genetic Destruction

Flagicure (Metronidazole) operates as a prodrug that must be chemically activated inside the target pathogen. This activation is uniquely dependent on low-redox potential enzymes, such as ferredoxin, found solely in obligate anaerobic bacteria and certain protozoa. This selective activation is the cornerstone of the drug’s mechanism, defining the cytotoxicity spectrum that is confined to these specific microorganisms.

Upon intracellular reduction, the drug generates highly reactive, short-lived nitro free radicals that function as powerful cytotoxic agents. These radicals immediately and irreversibly damage the pathogen's DNA by causing strand breaks and functional impairment, which subsequently leads to the inhibition of nucleic acid synthesis. This destructive molecular cascade produces a definitive bactericidal and amebicidal effect, causing organism death.

This mechanism exhibits high selective toxicity because the activating enzymes are absent in host cells. However, its action is critically inhibited by oxygen, which interferes with the necessary low-redox environment, functionally restricting the mechanism's spectrum of activity to obligate anaerobes.

Dosage and Administration Information

How to Use Flagicure: Administration Guidelines

Flagicure (metronidazole) is administered based on indication-specific parameters. The primary route of administration is either Oral (for home or outpatient use) or Intravenous (IV) (for severe infections or surgical settings). Local forms such as topical or vaginal preparations are also used for specific localized conditions.


Standardized Dosing and Frequency

Dosage is determined by the infection being treated, often ranging from mathbf250 mg to mathbf750 mg per dose. For systemic anaerobic infections, a common maintenance dose is mathbf7.5 mg/kg administered every mathbf6 to mathbf8 hours. Conversely, some protozoal conditions may be treated with a single mathbf2 g dose or a mathbf7-day course of a lower, divided dose, defining a short-term use pattern.


Administration Requirements and Duration

Specific contextual intake conditions apply to oral forms. Immediate-release tablets and capsules may be taken without regard to meals. However, extended-release tablets must be taken on an empty stomach (one hour before or two hours after eating). For IV administration, the solution must be infused over a mathbf30 to mathbf60-minute period, and the intravenous solution must not be exposed to aluminum-containing equipment. The typical course duration for most acute treatments is limited to mathbf7 to mathbf10 days, with prolonged use requiring close monitoring.


Population-Specific Adjustments

Dose reduction is utilized for patients with severe hepatic impairment (liver disease) due to the drug's metabolism. Pediatric dosing is weight-based for certain indications. For patients undergoing hemodialysis, supplemental doses may be necessary following the dialysis session to compensate for drug removal.

Recent Clinical Evidence

Evidence for Anaerobic and Deep-Seated Infections

Research examined Flagicure for use in serious intra-abdominal and deep anaerobic infections through Randomized Controlled Trials (RCTs) and Systematic Reviews. These studies primarily monitored measured changes in infection status and the rate of organism status in cohorts including hospitalized adults and critically ill infants. Findings describe patterns observed related to measured variables over defined time intervals. Research concerning use as a stand-alone treatment remains limited, as combination therapy is frequently observed, and long-term effects are not fully established.


Evidence for Specific Protozoal Infections

Research examined Flagicure for specific parasitic infections, including trichomoniasis and amebiasis. Studies explored outcomes related to measurements of microorganism status and observed changes in associated symptoms. For amebiasis, studies monitored protocols where co-administering a second agent was observed to be common to achieve full clearance and prevent long-term recurrence, meaning the evidence is limited regarding use without this complementary agent. Evidence also highlights a measured potential for re-infection or recurrence in trichomoniasis.


Evidence for Localized Infections and Topical Use

Research examined Flagicure for Bacterial Vaginosis (BV), exploring measured changes in the microbiological status and the rate of recurrence. Research also explored the topical application for rosacea in placebo-controlled trials, measuring the measured change in the number of inflammatory lesions and the severity score for facial redness. Results apply only to the specific populations studied; evidence is limited regarding the use of the drug in pregnancy for BV.


Evidence in Special Populations and Research Gaps

Flagicure was studied for use in special populations, including critically ill infants and patients with pre-existing liver or kidney impairment. Findings indicate that in these specific groups, there may be different patterns of metabolism. Data for certain groups remain insufficient, and research is ongoing. Long-term effects are not fully established for many conditions, as follow-up durations were limited in the primary research. The evidence highlights what is known—and what is still uncertain, with findings sometimes mixed when comparing different treatment schedules.

Frequently Asked Questions (FAQ)

Common questions about Flagicure (FAQ)

Q: Is it safe to drink alcohol while taking Flagicure?

A: Official guidance states that alcohol and products containing propylene glycol are formally advised to be avoided during Flagicure therapy and for at least three days after the medicine is stopped. This avoidance is necessary due to the documented risk of experiencing a severe reaction, known as a disulfiram-like reaction.

Q: What should be done if a dose is missed?

A: Patient information documents generally describe taking a missed dose as soon as it is remembered. However, if it is nearly time for the next scheduled dose, the missed dose should typically be skipped, and the regular schedule should be resumed. Patient information states that the next dose should not be doubled.

Q: Are there any long-term effects associated with using Flagicure?

A: Official safety information documents note the potential for peripheral neuropathy (a condition causing numbness, tingling, or pain in the limbs) with prolonged administration. The FDA label also includes a Black Box Warning regarding the potential for cancer observed in animal studies, necessitating that its use be restricted to approved indications.

Q: Is Flagicure only for short-term use?

A: The typical course of treatment for most acute infections is limited to 7 to 10 days. The official labeling notes that prolonged use beyond the recommended duration is permitted under careful patient monitoring, particularly for potential neurological adverse reactions.

Q: Can I stop taking Flagicure suddenly?

A: Official patient instructions often state that the medicine should be taken for the full duration prescribed by a healthcare provider. Stopping the medicine early, even if symptoms begin to improve, is not generally advised and may affect the outcome of the treatment course.

Q: Why is it important to know about Flagicure's interactions?

A: Knowing about interactions is important because co-administering Flagicure with certain substances, such as alcohol or the drug Disulfiram, can lead to severe, documented reactions. Flagicure can also change the way other prescription medicines are processed by the body, potentially increasing or decreasing their concentration.

Q: Why is Flagicure sometimes used for different ailments?

A: Flagicure is used for different types of infections because its unique mechanism of action targets two distinct types of microorganisms. It is effective against both obligate anaerobic bacteria (a type of germ that thrives without oxygen) and certain types of protozoa (single-celled parasites).

Q: Will Flagicure affect my sleep?

A: The official list of adverse reactions includes trouble sleeping (known as insomnia) among the more commonly reported effects. Less commonly reported effects include feeling sleepy or dizzy, according to official product information.

Q: Does Flagicure cause weight gain or loss?

A: Official adverse event lists indicate that weight loss is listed among the more commonly reported side effects experienced by some patients using Flagicure.

Q: Are there any dietary restrictions or foods to avoid with Flagicure?

A: In addition to avoiding alcohol, official warnings advise avoiding products that contain propylene glycol, which is a common additive found in certain foods, liquids, and medications. This is because combining it with Flagicure can result in a similar adverse reaction to consuming alcohol.

Q: Can Flagicure be taken with other common over-the-counter medicines?

A: Official guidelines recommend informing a healthcare professional about all co-administered medicines. This includes over-the-counter drugs, vitamins, and supplements, to ensure the complete interaction profile is reviewed and to understand any potential effects on how the body processes Flagicure.

Q: Can Flagicure be used by children?

A: The safety and effectiveness of Flagicure are generally not established for use in the overall pediatric population. However, for the treatment of certain specific infections, such as amebiasis, dosing for children, when permitted, is typically weight-based.

Q: What do official documents say about Flagicure and pregnancy?

A: Official documents state that Flagicure should be used during pregnancy only if clearly needed. It is generally contraindicated (not recommended) during the first trimester of pregnancy when used specifically for the treatment of trichomoniasis.

Q: Can Flagicure be used by breastfeeding mothers?

A: The active ingredient in Flagicure is known to pass into breast milk. Official guidance indicates that use during breastfeeding should be reviewed by a healthcare professional, especially when long-term treatment is being considered, and notes that diarrhea has been reported in some breastfed infants.

Q: How is Flagicure eliminated from the body?

A: The primary way Flagicure and its byproducts are eliminated from the body is through the urine, with a smaller portion eliminated in the feces. This process is documented in the product's pharmacokinetic information.

Q: Is Flagicure known to cause drowsiness?

A: Drowsiness (feeling sleepy) is listed as one of the less common adverse reactions in official prescribing information. Patients should be aware of this potential effect.

Q: Will Flagicure affect my ability to drive or operate machinery?

A: Official warnings advise caution when performing tasks that require focus, such as driving or operating machinery. This is because Flagicure may cause side effects like dizziness, confusion, or visual disturbances.

Q: Has Flagicure been reviewed by the FDA or similar agencies?

A: Yes, the active ingredient in Flagicure, metronidazole, has been formally reviewed and approved by major regulatory agencies, including the FDA, for various systemic and local uses in the treatment of specific infections.

Q: Do other medicines make Flagicure less effective?

A: Yes, certain other medicines, such as Phenytoin and Phenobarbital, can cause the body to metabolize Flagicure faster. This acceleration can result in reduced plasma concentrations of Flagicure, which may affect the overall therapeutic concentration.

Q: Is it normal to feel a slight headache when starting Flagicure?

A: According to official product information, headache is listed among the most common adverse reactions reported with Flagicure use. This means it is a frequently observed effect.

Q: Can elderly patients use Flagicure?

A: Use in elderly patients is permitted but requires caution due to the increased likelihood of age-related changes in liver function. This may necessitate monitoring to account for potential delayed drug clearance.

Q: Are there any specific groups where Flagicure's benefits were mostly studied?

A: Research evidence themes mention studies that focused on specific groups, including hospitalized adults, critically ill infants, and patients with pre-existing liver or kidney impairment.

Q: What is the intended duration of effect after a dose?

A: The duration of the systemic concentration is related to the drug's half-life, which is approximately eight hours in healthy subjects. This factor is used to determine the required frequency of dosing (e.g., every 6 to 8 hours) to maintain adequate drug levels.

How should Flagicure be stored and disposed of?

How to Store and Dispose of Flagicure

Official labeling requires Flagicure (metronidazole) to be stored at Controlled Room Temperature (20 C to 25 C), with a mandatory need to be protected from light. The product must not be frozen and exposure to excessive heat must be minimized to maintain its stability. For container integrity, the medicine should be kept in the original container and remain tightly closed.

Child-Safety and Disposal

Flagicure must be stored out of the sight and reach of children; certain forms require a child-resistant closure. Disposal of unused or expired medicine should be done through a drug take-back program when available. If a program is not accessible, the official guidance is to mix the medicine with an undesirable substance before discarding it in the household trash; do not flush the product down the toilet or drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Flagicure found in:

A-Z Index: